Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
US Judge Dismisses Gautam Adani Criminal Charges 
Airbus Joins Air India A320 Altitude Drop Probe 
ADNOC Gas Targets Up to $4B Profit in 2026 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
BOSTON, Feb. 20, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Chief Medical Officer, will present a company overview at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018 at 2:05 p.m. ET in New York.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
